A Multicenter, Prospective, Self - controlled study of Idebenoneon in Patients with Spinocerebellar Ataxias

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200060666

Enrollment

Unknown

Registered

2022-06-06

Start date

2022-06-09

Completion date

Unknown

Last updated

2024-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spinocerebellar ataxia

Interventions

Idebenone Tablets:Take Idebenoneon

Eligibility

Sex/Gender

All

Age

15 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1) Clinically diagnosed as SCA patients or confirmed as SCA patients after genetic testing; 2) have corresponding symptoms of ataxia or other clinical symptoms of SCA; 3) Signing informed consent, etc.; 4) Ages 15-70.

Exclusion criteria

Exclusion criteria: 1) Ataxia caused by other causes; 2) complicated with other serious neurological diseases; 3) Cognitive dysfunction caused by other reasons; 4) History of drug allergy; 5) Pregnant women, etc.; 6) Critical patients with unstable vital signs; 7) Can not adhere to long-term visitors; 8) Failure to obtain informed consent.

Design outcomes

Primary

Measure	Time frame
Clinical symptoms relief;	—

Secondary

Measure	Time frame
Montreal Cognitive Assessment, MoCA;Scale for the assessment and rating of ataxia (SARA);	—

Countries

China

Contacts

Public ContactLiu Xuewu

Qilu Hospital of Shandong University

snlxw1966@163.com18560085520

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026